On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY J&J’s Subcutaneous Rybrevant Faces Delay in Japan Approval Process
September 17, 2025
-
BUSINESS Alnylam Sees Japan Business Doubling as Amvuttra Expands into ATTR-CM
September 17, 2025
-
BUSINESS Predictability Key to Novartis’ Japan Investment, Says International Chief
September 16, 2025
-
BUSINESS LEO Pharma Reinforces Japan Push toward Dermatology Leadership
September 12, 2025
-
BUSINESS Sawai and T’s Pharma Won Forxiga Generics by Skirting Patent, Will the Strategy Hold?
September 11, 2025
-
REGULATORY Reblozyl Faces Price Cut after Cost-Effectiveness Assessment
September 11, 2025
-
BUSINESS Teijin Pharma Bets on Ascendis Rare Disease Assets as Feburic Sales Crumble
September 10, 2025
-
BUSINESS Amicus CEO Confident on US$1 Billion Sales Target as Japan Pompe Launch Gets Underway
September 9, 2025
-
BUSINESS KM Biologics Developing Higher-Yield Liquid Immunoglobulin to Boost Efficiency and Supply
September 8, 2025
-
ORGANIZATION JPMA Code & Compliance Chair Stresses Need to Embed Spirit of Revised COP
September 8, 2025
-
COMMENTARY MHLW Grows Jittery over Supply Risks amid Rising Foreign Investments
September 8, 2025
-
BUSINESS And Pharma Chief Pledges Growth Strategy as New Generics Holding Firm Takes Shape
September 5, 2025
-
ORGANIZATION JPMA ICH Project Chair Sees RWE as Potential Complement to Clinical Trials
September 5, 2025
-
BUSINESS Bayer Pushes Cross-Border Open Innovation with New Co.Lab Connect Program
September 4, 2025
-
ORGANIZATION JPMA Regulatory Chief Seeks Balanced Approach on Japanese PI Waivers
September 3, 2025
-
REGULATORY Pharma Groups Press Pricing Reform at First Public-Private WG Meeting
September 2, 2025
-
REGULATORY Japan Panel Clears Izervay, Nexletol for Approval; Eylea Biosimilars Edge Ahead Too
September 1, 2025
-
REGULATORY METI Proposes “Bold Investment” Tax Breaks in FY2026 Request
September 1, 2025
-
REGULATORY Japan Panel Green Lights Nonprescription Switch of Morning-After Pill
September 1, 2025
-
REGULATORY MHLW Orders Label Revision for Elevidys to Add Acute Hepatic Failure
September 1, 2025
ページ
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…